Co-Diagnostics, Inc. 8-K

What Happened

• On March 31, 2026 Co‑Diagnostics, Inc. (CODX) announced and furnished a press release reporting its financial results for the year ended December 31, 2025. The press release is included as Exhibit 99.1 to the Form 8‑K and the filing notes the release includes information about the Company’s use of a non‑GAAP financial measure. The Form 8‑K also references Regulation FD disclosure.

Key Details

• Date filed: March 31, 2026 (Form 8‑K furnished to the SEC).
• Reporting period: Year ended December 31, 2025.
• Exhibit: Press Release dated March 31, 2026 furnished as Exhibit 99.1.
• Non‑GAAP: Press release includes discussion/use of a non‑GAAP financial measure (per the filing).

Why It Matters

• This filing provides investors with Co‑Diagnostics’ latest annual financial results and management commentary (earnings and related metrics). Because the release includes non‑GAAP measures, investors should review the press release and any reconciliations to GAAP amounts to understand differences in reported performance. The 8‑K is a routine disclosure of results rather than a transaction or leadership change, but the announced figures can influence investor decisions and the stock’s near‑term reaction.